Literature DB >> 25006011

Serological and clinical outcomes of horizontally transmitted chronic hepatitis B infection in New Zealand Māori: results from a 28-year follow-up study.

Tien Huey Lim1, Edward Gane1, Chris Moyes2, Barry Borman3, Chris Cunningham4.   

Abstract

BACKGROUND: Chronic hepatitis B infection is endemic in New Zealand and has high prevalence in New Zealand Māori. Previous longitudinal studies in populations with predominantly vertically acquired chronic hepatitis B have shown low spontaneous hepatitis B surface-antigen (HBsAg) seroclearance rates: 0.5-1.4% annually (mean age of clearance 48 years). We report the 28-year follow-up data on clinical and serological outcomes in indigenous New Zealand Māori with early horizontally acquired HBV.
METHODS: In 1984, community seroprevalence study identified 572 HBsAg-positive individuals, followed for 28 years. Liver-related mortality and hepatocellular carcinoma (HCC) incidence were compared between these 572 HBV carriers and 1140 HBsAg-negative matched case-controls. Surviving HBsAg-positive individuals have been followed up in 2012 with clinical assessment, blood tests and liver transient elastography. Rates of hepatitis B e-antigen (HBeAg) and HBsAg seroconversion were determined.
RESULTS: After total 13 187.4 person-years follow-up, 15 HBsAg-positive patients have developed HCC compared with none of the HBsAg-negative controls (p<0.001). 12 HBsAg-positive patients died from liver-related causes compared with none in the controls (p<0.001). Spontaneous HBeAg-seroconversion occurred in 91% of HBeAg-positive patients. Spontaneous HBsAg loss occurred in 33% overall (annual clearance rate 1.34%), with higher rates at older ages (1.05% in patients<20 years at entry vs 4.3% per annum >40 years at entry, p<0.0001). Median ages of HBeAg loss and HBsAg loss were 23 years (range 6-66 years) and 40 years (range 4-80 years), respectively.
CONCLUSIONS: Horizontally transmitted HBV in Maori is similarly associated with increased risk of liver-related mortality and HCC compared with Chinese, although absolute incidence rates are lower. The rates of HBeAg and HBsAg loss are high, and occur at an earlier age than previously reported. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  HEPATITIS B; HEPATOCELLULAR CARCINOMA

Mesh:

Year:  2014        PMID: 25006011     DOI: 10.1136/gutjnl-2013-306247

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  12 in total

1.  Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobulin treatment: a case study in Zhejiang Province, East China.

Authors:  Yanbing Zeng; Mingliang Luo; Jianlin Lin; Hanqing He; Xuan Deng; Shuyun Xie; Ya Fang
Journal:  Hum Vaccin Immunother       Date:  2019-11-26       Impact factor: 3.452

2.  Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses.

Authors:  Kali Zhou; Caitlin Contag; Evans Whitaker; Norah Terrault
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-01-22

3.  HBsAg loss in a New Zealand community study with 28-year follow-up: rates, predictors and long-term outcomes.

Authors:  Tien Huey Lim; Edward Gane; Chris Moyes; Barry Borman; Chris Cunningham
Journal:  Hepatol Int       Date:  2016-03-08       Impact factor: 6.047

4.  Ethnic differences in incidence of hepatitis B surface antigen seroclearance in a real-life multicenter clinical cohort of 4737 patients with chronic hepatitis B infection.

Authors:  L H Nguyen; J Hoang; N H Nguyen; V D Vu; C Wang; H N Trinh; J Li; J Q Zhang; M H Nguyen
Journal:  Aliment Pharmacol Ther       Date:  2016-07-01       Impact factor: 8.171

5.  A "one stop liver shop" approach improves the cascade-of-care for Aboriginal and Torres Strait Islander Australians living with chronic hepatitis B in the Northern Territory of Australia: results of a novel care delivery model.

Authors:  Thel K Hla; Sarah M Bukulatjpi; Paula Binks; George G Gurruwiwi; Roslyn G Dhurrkay; Jane Davies
Journal:  Int J Equity Health       Date:  2020-05-07

6.  Real-world study on clinical outcomes of nucleos(t)ide analogues antiviral therapy in patients with chronic hepatitis B.

Authors:  Y Sun; Y Zhang; Y Xu; M Shu; K Bonroy; H Qiu; W Cai
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

7.  Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B.

Authors:  Patrick Marcellin; Qing Xie; Seung Woon Paik; Robert Flisiak; Teerha Piratvisuth; Jörg Petersen; Tarik Asselah; Markus Cornberg; Denis Ouzan; Graham R Foster; Georgios Papatheodoridis; Diethelm Messinger; Loredana Regep; Georgios Bakalos; Ulrich Alshuth; Pietro Lampertico; Heiner Wedemeyer
Journal:  PLoS One       Date:  2020-04-10       Impact factor: 3.240

8.  Cost-effectiveness of couple-based immunization strategy to prevent mother-to-child transmission of hepatitis B virus in China: A decision-analytic Markov model.

Authors:  Wenzhan Jing; Jue Liu; Yu Wu; Qiuyue Ma; Min Liu
Journal:  EClinicalMedicine       Date:  2020-02-04

9.  Clinical features of HBsAg seroclearance in hepatitis B virus carriers in South Korea: A retrospective longitudinal study.

Authors:  Young Min Park; Seong Gyu Lee
Journal:  World J Gastroenterol       Date:  2016-11-28       Impact factor: 5.742

10.  Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients.

Authors:  Yee Hui Yeo; Tai-Chung Tseng; Tetsuya Hosaka; Chris Cunningham; James Yan Yue Fung; Hsiu J Ho; Min-Sun Kwak; Huy N Trinh; Teerapat Ungtrakul; Ming-Lung Yu; Mariko Kobayashi; An K Le; Linda Henry; Jiayi Li; Jian Zhang; Tassanee Sriprayoon; Donghak Jeong; Tawesak Tanwandee; Ed Gane; Ramsey C Cheung; Chun-Ying Wu; Anna S Lok; Hyo-Suk Lee; Fumitaka Suzuki; Man-Fung Yuen; Jia-Horng Kao; Hwai-I Yang; Mindie H Nguyen
Journal:  Clin Transl Gastroenterol       Date:  2020-09       Impact factor: 4.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.